Literature DB >> 9598145

Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies.

T Ueda1, S Matsuyama, T Yamauchi, S Kishi, T Fukushima, H Tsutani, T Nakamura, N Gotoh, M Masada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9598145     DOI： 10.1007/978-1-4615-5381-6_125

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  3 in total

1.  Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.

Authors:  Elisabeth Ersvaer; Annette K Brenner; Kristin Vetås; Håkon Reikvam; Øystein Bruserud
Journal:  BMC Pharmacol Toxicol       Date:  2015-05-02       Impact factor: 2.483

2.  Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.

Authors:  T Yamauchi; Y Kawai; S Kishi; N Goto; Y Urasaki; S Imamura; T Fukushima; A Yoshida; H Iwasaki; H Tsutani; M Masada; T Ueda
Journal:  Jpn J Cancer Res       Date:  2001-05

3.  1-beta-D-arabinofuranosylcytosine is cytotoxic in quiescent normal lymphocytes undergoing DNA excision repair.

Authors:  Takahiro Yamauchi; Yasukazu Kawai; Takanori Ueda
Journal:  Jpn J Cancer Res       Date:  2002-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.